Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sarkozy to launch rare disease initiative

This article was originally published in Scrip

Executive Summary

Nicolas Sarkozy, France's president, says he will develop a second national plan for rare diseases next year and put it in place by 2010 at the latest. He has also agreed that the funding established previously for national rare disease reference centres – there are around 100 hospital-based co-ordinating centres in France, each specialised in a rare disease – would be made permanent (Scrip Online, February 8th, 2006). Mr Sarkozy said rare diseases were a priority during France's current presidency of the European Union, estimating that 30 million Europeans suffer a rare disease. A communication on the subject from the European Commission is expected before the end of the year. The Alliance Maladies Rares, a French patient organisation, welcomed news of the plan, saying the first plan had not met all of its objectives.Leem, the French pharmaceutical industry association, hopes that research will be a key element in the second plan.

You may also be interested in...



Cervarix link to UK girl's death "unlikely"

Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.

Generic Topamax launched in European markets

Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.

NICE confirms limits on Alimta for lung cancer

Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.

Topics

UsernamePublicRestriction

Register

OM004514

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel